Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2012-002002-46-AT
EUCTR2012-002002-46-AT
Active, not recruiting
Phase 1

A phase III, randomized, controlled clinical pilot trial of lateral ridge augmentation using autogenous bone blocks or xenogenic bone block grafts loaded with recombinant human bone morphogenic protein 2 - BMP2

niversitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie0 sites24 target enrollmentApril 4, 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsDifference of percepetion/acceptance in patients trated with autogonous bone blocks or xenogenic bone block loaded with BMP2 to create a sufficent bonesituation Difference in quantity and quality of the augmented boneMedDRA version: 14.1 Level: PT Classification code 10064143 Term: Dental implantation System Organ Class: 10042613 - Surgical and medical proceduresTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Dentistry [E06]
DrugsInductOs

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Difference of percepetion/acceptance in patients trated with autogonous bone blocks or xenogenic bone block loaded with BMP2 to create a sufficent bonesituation Difference in quantity and quality of the augmented bone
Sponsor
niversitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie
Enrollment
24
Status
Active, not recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 4, 2013
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional clinical trial of medicinal product

Investigators

Sponsor
niversitätsklinik für Zahn-, Mund- und Kieferheilkunde, Med Uni Graz, Department für zahnärztliche Chirurgie

Eligibility Criteria

Inclusion Criteria

  • •patients requiring implant therapy for the reconstruction of 1 to 4 missing teeth
  • •patients revealing insufficient bone volume for implant placement
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) yes
  • •F.1\.2\.1 Number of subjects for this age range 8
  • •F.1\.3 Elderly (\>\=65 years) yes
  • •F.1\.3\.1 Number of subjects for this age range 4

Exclusion Criteria

  • •severe diseases
  • •medications with a contraindication for implant therapy
  • •insufficent bone volume for harvesting a autogenous block
  • •pregnancy and breast feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005731-41-IEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
Completed
Phase 3
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma
NL-OMON45288Merck Sharp & Dohme (MSD)20
Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 19.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005731-41-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005731-41-GBMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990
Active, not recruiting
Phase 1
Phase III Randomized Controlled Trial of Pembrolizumab with or without Chemo vs Chemo in Advanced Urothelial CarcinomaAdvanced or Metastatic Urothelial CarcinomaMedDRA version: 20.0Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2015-005731-41-BEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.990